Skip to main content
. Author manuscript; available in PMC: 2016 Mar 3.
Published in final edited form as: Ann Rheum Dis. 2013 Apr 20;73(6):1060–1066. doi: 10.1136/annrheumdis-2012-202849

Figure 1.

Figure 1

A, Percentage of patients with Type-0 (n=81), Type-1 (n=1070), Type-2 (n=197), and Type-3 (n=857) scleroderma with evidence of RLD (FVC<80%) at their first pulmonary function test (*p<0.001, **p=0.03). B, Percentage of patients in each subtype analyzed by severity of restrictive lung disease: none (FVC>80% predicted), mild (FVC 70-80% predicted), moderate (FVC 50-69% predicted), or severe (FVC<50% predicted) (*p<0.001). RLD = restrictive lung disease; PFT = pulmonary function test; FVC = forced vital capacity (% of predicted)